You are here Home India Operations
Pharmaceuticals

Currently ranked at 11th in the Indian Pharmaceutical Market, Intas is one of the fastest growing Indian pharmaceutical majors, having 2.9% market share1. Driven by a sustainable business model, Intas has been consistently outperforming the market with a 15%* CAGR. Its 8 Strategic Business Units employ a multidivisional model, with 35 marketing divisions catering to various therapy areas for enhanced focus towards brand development. On the foundation of this diversified revenue base, Intas has gained dominant presence in India with an expanding market share and improving ranks across years.

50% of Intas' total domestic revenue is generated from Neurology, Psychiatry and Cardiovascular therapies. The current emphasis is on Central Nervous System (CNS), Nephrology, Cardiovascular, Diabetology, Gastroenterology, Urology and Pain Management therapies. While Intas enjoys leadership status (2nd) in the CNS segment, it has also been rapidly gaining equity in Oncology, Rheumatology, Ophthalmology, Dermatology and Infertility segments.

Intas enjoys exhaustive coverage of key specialties like Neurologists, Psychiatrists, Cardiologists, Diabetologists, Consulting Physicians, Urologists, Nephrologists & Oncologists with a substantial* prescriber base. The company operates through 40 exclusive and dedicated sales depots and has established relationships with over 4,000 stockists in India. A dedicated sales representative team of 6,000+ covers more than 2,50,000 medical practitioners and 1,50,000 retail outlets across geographies including metro markets, semi-urban markets and rural markets. Intas also has well-spread institutional presence with coverage of over 600 corporate hospitals & nursing homes.

The company is set to enhance its presence in the market through its active progress in NDDS. Currently, Intas has launched 3 NDDS products in India using patented technology.

Intas' ten state-of-the-art manufacturing facilities in India cater to the domestic demand by producing various dosage forms including solid orals, biosimilars, liquids, lyophilized sterile preparations, creams, drops and injectables.

#1 : IMS TSA MAT Jul 2018, CAGR of last 5 years,: *substantial – indicating a base of over 75%